Equillium (EQ) Non Operating Income (2018 - 2024)
Equillium (EQ) reported Non Operating Income of $57000.0 for Q1 2024, down 75.0% year-over-year from $228000.0 in Q2 2023, and down 93.53% quarter-over-quarter from $881000.0 in Q4 2023.
Equillium (EQ) Non Operating Income (2018 - 2024) Analysis & Trends
Equillium (EQ) has 7 years of Non Operating Income data on file, last reported at $57000.0 in Q1 2024.
- Non Operating Income for Q1 2024 came in at $57000.0, down 75.0% year-over-year; the trailing twelve-month figure through Mar 2024 was $684000.0 (up 86.89% YoY), and the FY2025 annual result was $262000.0, down 46.31% from the prior year.
- Non Operating Income retreated to $57000.0 in Q1 2024 per EQ's latest filing, from $881000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $881000.0 in Q4 2023 and troughed at -$994000.0 in Q4 2021.
- A 5-year average of -$44235.3 and a median of -$112000.0 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2020 and 2021: Non Operating Income jumped 1050.0% in 2020, then slumped 2011.54% in 2021.
- A 5-year view of Non Operating Income shows it stood at $52000.0 in 2020, then tumbled by 2011.54% to -$994000.0 in 2021, then soared by 180.58% to $801000.0 in 2022, then increased by 9.99% to $881000.0 in 2023, then slumped by 93.53% to $57000.0 in 2024.
- Business Quant data shows EQ's Non Operating Income at $57000.0 in Q1 2024, $881000.0 in Q4 2023, and -$142000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 57,000.00 |
| Dec 31, 2023 | 881,000.00 |
| Sep 30, 2023 | -142,000.00 |
| Jun 30, 2023 | -112,000.00 |
| Mar 31, 2023 | 228,000.00 |
| Dec 31, 2022 | 801,000.00 |
| Sep 30, 2022 | -281,000.00 |
| Jun 30, 2022 | -382,000.00 |
| Mar 31, 2022 | 142,000.00 |
| Dec 31, 2021 | -994,000.00 |
| Sep 30, 2021 | -421,000.00 |
| Jun 30, 2021 | -315,000.00 |
| Mar 31, 2021 | -296,000.00 |
| Dec 31, 2020 | 52,000.00 |
| Sep 30, 2020 | 114,000.00 |
| Jun 30, 2020 | 301,000.00 |
| Mar 31, 2020 | -385,000.00 |
| Dec 31, 2019 | 49,000.00 |
| Sep 30, 2019 | -12,000.00 |
| Jun 30, 2019 | 370,000.00 |